# US 2022/0031803 A1 · Antibacterial composition comprising microcin s and antibiotic

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031803 A1
- Document ID: US20220031803A1
- Status: Published application
- Kind: A1
- Application number: 17/389,064
- Filed: 2021-07-29
- Published: 2022-02-03
- Earliest claimed: 2017-11-29
- Assignees: SymbioGruppe GmbH & Co. KG
- Applicants: SymbioGruppe GmbH & Co. KG
- Inventors: Kurt ZIMMERMANN; Christian AUERBACH; Florian GUNZER
- Web page: https://patentgrep.com/patent/US20220031803A1

## CPC

- A61K 38/164: {from bacteria}
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 31/02: Local antiseptics
- A61P 31/04: Antibacterial agents
- C07K 14/245: Escherichia (G)
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A composition comprising an antimicrobial polypeptide and at least one antibiotic.

## Claims

### Claim 1

A composition comprising an antimicrobial polypeptide and at least one antibiotic, wherein the antimicrobial polypeptide is an amino acid sequence which is at least 90% identical to the amino acid sequence SEQ ID NO:6 or SEQ ID NO:7; or
microcin S, and wherein
the antibiotic is a polypeptide antibiotic.

### Claim at position 2

2-7. (canceled)

### Claim 8 (depends on 1)

The composition according to claim 1, characterized in that the composition comprises a quantity of microcin S and antibiotic that is suitable for achieving a synergistic antimicrobial effect.

### Claim 9

A pharmaceutical composition comprising an antimicrobial polypeptide and at least one antibiotic, wherein the antimicrobial polypeptide is an amino acid sequence which is at least 90% identical to the amino acid sequence SEQ ID NO:6 or SEQ ID NO:7, or
microcin S, and wherein
the antibiotic is a polypeptide antibiotic.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, characterized in that the composition comprises pharmaceutically tolerable excipients.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, characterized in that it is present as tablet, sugar-coated tablet, liquid, powder, or ointment.

### Claim 12 (depends on 9)

A method of treatment or prophylaxis of bacterial infectious diseases characterized in that a pharmaceutically effective amount of a composition according to claim 9 is administered to a subject in need thereof.

### Claim 13 (depends on 12)

The method according to claim 12, characterized in that the bacterial infectious diseases are caused by enteropathogenic and/or enterohaemorrhagic Escherichia coli or are associated with haemolytic uraemic syndrome.

### Claim 14 (depends on 12)

The method according to claim 12, characterized in that the treatment or prophylaxis of bacterial infectious diseases involves the treatment or prophylaxis of gastrointestinal disorders or diseases, septic symptoms, multi-resistant pathogens, or sepsis with multi-resistant pathogens.

### Claim 15 (depends on 9)

The pharmaceutical composition according to claim 9, characterized in that it is present as tablet, sugar-coated tablet, liquid, powder, or ointment.
